Media headlines about Calithera Biosciences (NASDAQ:CALA) have been trending somewhat positive on Saturday, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Calithera Biosciences earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.9101747950877 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of NASDAQ:CALA traded down $0.40 during trading on Friday, reaching $5.45. 879,126 shares of the company were exchanged, compared to its average volume of 528,710. The firm has a market cap of $209.48, a PE ratio of -6.49 and a beta of 2.62. Calithera Biosciences has a 12-month low of $5.35 and a 12-month high of $20.05.
Calithera Biosciences (NASDAQ:CALA) last issued its earnings results on Thursday, March 8th. The biotechnology company reported ($0.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.09). The company had revenue of $7.24 million for the quarter, compared to analysts’ expectations of $7.28 million. Calithera Biosciences had a negative return on equity of 17.49% and a negative net margin of 107.21%. During the same period last year, the business posted ($0.45) earnings per share. sell-side analysts expect that Calithera Biosciences will post -1.21 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Calithera Biosciences (CALA) Getting Somewhat Positive Media Coverage, Study Shows” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3339097/calithera-biosciences-cala-getting-somewhat-positive-media-coverage-study-shows.html.
About Calithera Biosciences
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.